On Friday, ToolGen Inc., a South Korean biotech firm, inaugurated a research and development (R&D) center in Cheongju to further its advancement of gene editing technology, according to company officials.
The facility is equipped with state-of-the-art equipment to investigate seed development, including a walk-in chamber and a speed breeding chamber.
ToolGen is the only South Korean corporation that holds a patent for the CRISPR-Cas9 foundational technology.
CRISPR-Cas9, developed in 2012, is a gene editing method that permits the highly precise and prompt modification of DNA in a genome, following earlier gene editing techniques of Zinc Finger (ZFN) and Transcription Activator-Like Effector Nucleases.
“The R&D center will serve as a base for the company’s global business, including business expansion, technology transfer, and sales,” said ToolGen CEO Lee Byong-hwa.
Officials of ToolGen Inc., a South Korean biotech company, attends a construction completion ceremony of its research and development center in Cheongju, about 110 kilometers south of Seoul, on Oct. 13, 2023, in this photo provided by the company. (PHOTO NOT FOR SALE) (Yonhap)
nyway@yna.co.kr
(END)
Related Articles S. Korea, Saudi Arabia agree to enhance cooperation on wider industry fields S. Korea to send delegation to major Baltic bio forum